Sepax Technologies Completes Series C Financing of Over RMB 200 Million to Strengthen Leadership in Biomolecular Chromatographic Separation Technology

Recently, SuZhou Sepax Technologies Co., Ltd. (“Sepax Technologies”) announced the completion of its Series C financing round, raising over RMB 200 million. This round introduced heavyweight strategic investors, including China Life Health Industry Fund and Fosun. Following this financing, Sepax Technologies will continue to solidify its leadership position in the field of chromatographic separation technologies for biomacromolecules, while accelerating the enhancement of R&D, production, and operational capabilities across its business segments, including analytical chromatography, industrial purification, and medical diagnostics.

Sepax Technologies, Inc. was founded in 2002 in the High-Tech Development Zone of Delaware, USA, dedicated to the research, development, and industrialization of chromatography technologies for biopharmaceutical separation and purification. Its analytical chromatography expertise and comprehensive product portfolio have gained widespread recognition from multinational pharmaceutical companies and leading players in the chromatography industry.

In 2009, SuZhou Sepax Technologies Co., Ltd. was established in Suzhou Industrial Park, focusing on research and development and operations in the Chinese market, with a commitment to building a leading Chinese brand in the field of chromatography technology.

In 2017, Yangzhou Sepax Technologies Co., Ltd. was established, focusing on the large-scale production of chromatography media. By the end of 2020, the Yangzhou production base had officially commenced operations, with four production lines completed in Phase I, achieving an annual capacity of 100,000 liters. Leveraging international chromatography technologies and domestically based production facilities, Sepax Technologies is committed to creating value for China’s biopharmaceutical industry, striving to become a modern, standardized, and large-scale high-end manufacturer with global competitiveness.

SuZhou Sepax Technologies Co., Ltd. is an enterprise under the National Talent Program and a High-Tech Enterprise in Jiangsu Province. The company holds extensive intellectual property rights, including more than 20 granted patents in the United States and China, 14 registered trademarks, as well as substantial technical know-how and trade secrets. Its quality management system has been separately certified to ISO 9001 standards in both the United States and China. Over 800 articles and publications featuring Sepax Technologies’ products have been published internationally.

As a company that has been deeply engaged in chromatography technology for nearly two decades, Sepax Technologies possesses fully independent proprietary technologies. Its product portfolio covers affinity, ion exchange, hydrophobic interaction, size exclusion, and reversed-phase chromatography columns and media, which are widely used in the analysis, separation, and purification of biological samples such as antibodies, antibody-drug conjugates (ADCs), various proteins, insulin, and vaccines. The localization of chromatography media is an inevitable path for the rise of China's biopharmaceutical industry, and the global pandemic environment will accelerate this domestication process. This financing round will enable Sepax Technologies to play a more significant role in ensuring the security of China's biopharmaceutical supply chain, controlling costs, and providing technical support for separation and purification.

Dr. Xueying Huang, Chairman of Sepax TechnologiesStatement: The world is currently undergoing profound changes unseen in a century. China's biopharmaceutical industry is rapidly advancing towards large-scale production and product diversification, and is poised to reach world-class standards in the near future, becoming one of China's pillar industries. As key and core materials for the industrialization of biopharmaceuticals, the large-scale domestic production of chromatography resins and media is imperative. Seizing this historic opportunity, Sepax Technologies will continue to dedicate itself to addressing high-end core technical challenges in the field of separation and purification. By providing indispensable key technologies and materials, we aim to support the rise of China's biopharmaceutical industry and create value for Chinese biopharmaceutical enterprises.

Zhang Leidi, Head of China Life Capital Investment LimitedStatement: China’s biopharmaceutical industry is flourishing, with core raw materials and key technological segments gradually breaking free from import monopolies. Sepax Technologies is one of the few companies worldwide capable of overcoming technical barriers across the entire chromatography separation industry chain. Its foundational technological capabilities have reached international standards, and the performance of its core products rivals that of global giants, indicating significant potential for domestic substitution. China Life Health Industry Fund aims to partner with and support Sepax Technologies in continuously innovating to conquer critical “chokepoint” technologies in the biopharmaceutical sector, thereby enhancing the supply security of key biopharmaceutical raw materials and making positive contributions to China’s industrial transformation and upgrading.

Zhang Min, Managing Director of Fosun InvestmentStatement: With the rapid development of China's biopharmaceutical industry, the core materials and technologies in the upstream pharmaceutical sector are accelerating their localization process. Fosun continues to closely monitor the significant market opportunities arising from this trend. SuZhou Sepax Technologies Co., Ltd. has a clear strategic positioning, focusing on the field of biopharmaceutical separation and purification. Its technical strength has been highly recognized by numerous customers both domestically and internationally, and it possesses cutting-edge capabilities in technological R&D and industry resource integration. We are honored to participate in this financing round and have strong confidence in the future development of SuZhou Sepax Technologies. We look forward to working with its team to jointly promote the innovative development of China's biopharmaceutical industry and create greater value for the sector.

China Life Capital Investment Limited, established in June 2016, is a specialized private equity investment platform under China Life Insurance. Adhering to the investment philosophy of “investing in the future, innovation, and value,” the company leverages the professional advantages of insurance funds and China Life’s sense of responsibility to serve national strategies, support the real economy, and demonstrate China Life’s commitment and contributions.

China Life Healthcare Fund, initiated and established by China Life Capital Investment Limited in November 2016, is a leading flagship healthcare industry investment fund in China. It was also the first private equity fund funded by insurance capital to be approved following the issuance of relevant policies by the China Insurance Regulatory Commission (CIRC). Since its inception, the fund has achieved extensive investment coverage across life sciences, medical technology, healthcare services, and digital health, investing in a portfolio of leading enterprises in China’s healthcare sector.

Fosun’s investment in Sepax Technologies was jointly led and funded by its USD-denominated industrial fund and Fosun Chuangfu.

Fosun Chuangfu is a wholly-owned equity investment management company under Fosun Group. As a leading private equity investment firm in the industry, it provides high-quality equity investment management services to domestic and international investors, including renowned family funds, insurance companies, listed companies, large institutional investors, and high-net-worth individuals. The assets initiated and managed by Fosun Chuangfu include fund of funds, private equity investment funds, and industrial funds for listed companies, with assets under management exceeding RMB 20 billion. Fosun Chuangfu focuses on investments in six key sectors: intelligent manufacturing, environmental protection and new energy, fashion and consumer goods, TMT, healthcare, and automotive and industrial services. It has invested in nearly 100 companies, with more than 20 successfully listed or quoted on domestic or overseas stock exchanges.

Fosun USD Industrial Fund: Leveraging Fosun’s network, this USD-denominated private equity fund connects Fosun and its partners, focusing on the healthcare, consumer, and technology sectors. By tapping into Fosun’s global resources in talent, products, and technology, and through deep industrial operation, integration, and investment, the fund enables portfolio companies to benefit from growth drivers in global markets, supporting their continuous development and expansion into globally leading enterprises.